AstraZeneca PLC and Ionis Pharmaceuticals, Inc. obtained US Food and Drug Administration approval on 21 December for Wainua (eplontersen) in the treatment of adults with hereditary transthyretin mediated amyloidosis (ATTR) with polyneuropathy (ATTR-PN). Phase III data in ATTR cardiomyopathy are not expected until 2025, but AstraZeneca sees Wainua as an important addition to its cardiovascular disease portfolio, while Ionis views the drug as a big first step for its commercial organization.
AstraZeneca, Ionis Win A Key US FDA Approval With Wainua For ATTR Polyneuropathy
Drug Launches In January Under Co-Commercialization Deal
AstraZeneca adds an important product to its cardiovascular, renal and metabolism (CVRM) portfolio and Ionis gains the first drug it will commercialize as it prepares for its first wholly owned launch.
More from New Products
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.
• By
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.
More from Scrip
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.